Kaisa Health Group Holdings Limited announced a refreshed governance framework that will take effect on 13 July 2026, detailing appointments across the Board of Directors and its key committees.

The Board will comprise nine members—six Executive Directors and three Independent Non-Executive Directors. Executive leadership is anchored by Chairman Mr. Kwok Ying Shing, Vice Chairman Mr. Luo Jun, and Vice Chairperson Ms. Luo Tingting, alongside Mr. Xie Binhong, Mr. Yang Feng, and Mr. Ye Haoda.

Independent oversight is provided by Dr. Liu Yanwen, Dr. Lyu Aiping, and Ms. Li Zhiying, who also assume pivotal committee roles. Dr. Liu Yanwen chairs the Audit Committee, supported by Dr. Lyu Aiping and Ms. Li Zhiying. Remuneration matters will be led by Dr. Lyu Aiping, with Mr. Kwok Ying Shing and Dr. Liu Yanwen as members. Board nominations remain under the stewardship of Chairman Mr. Kwok Ying Shing, joined by Dr. Lyu Aiping and Ms. Li Zhiying.

The updated structure clarifies responsibilities across governance functions, highlighting Kaisa Health’s ongoing focus on board independence and oversight. All changes are effective as of 13 July 2026.